Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Transcatheter aortic valve replacement (TAVR) is a well-established alternative to surgical aortic valve replacement (SAVR) for the treatment of patients with severe aortic stenosis regardless of surgical risk. While TAVR and SAVR share some of the benefits and risks, they importantly differ with regards to invasiveness, time to recovery, hemodynamics, as well as options for re-intervention and possibly valve durability. An early benefit of TAVR may be offset by late risks. Therefore, current guidelines of the European Society of Cardiology recommend an integration of patient values and preferences for the selection of the treatment modality.
The objective of the TOGETHER trial is to investigate the efficacy of a structured shared decision making approach (SDM) to improve patient-centered outcomes for the choice between SAVR and TAVR.
TOGETHER is an investigator-initiated, randomized, open-label, single-center clinical trial. A total of 140 patients referred for treatment of symptomatic severe aortic stenosis and deemed to undergo TAVR or SAVR according to heart team decision will be randomized in a 1:1 ratio to structured SDM or usual care.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Structured SDM | Other | Structured shared decision making for the choice between SAVR and TAVR |
|
| Usual Care | Other | Usual care for the choice between SAVR and TAVR |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Structured SDM | Other | The conversation between the heart team member and the patient will be structured according the adapted three-talk model for patients with symptomatic aortic stenosis and using the American College of Cardiology's decision aid for patients deciding between TAVR and SAVR |
| Measure | Description | Time Frame |
|---|---|---|
| Patient decisional conflict | Assessed by decisional conflict scale (ranges from 0 to 100, with higher scores indicating a worse outcome) | 3 days post baseline visit |
| Patient decisional regret | Assessed by the decision regret scale (ranges from 0 to 100, with higher scores indicating a worse outcome) | 30 days post TAVR/SAVR |
| Measure | Description | Time Frame |
|---|---|---|
| Patient-centered communication | Assessed by CollaboRATE scale (ranges from 0 to 100, with higher scores indicating a better outcome) | 3 days post baseline visit |
| Patient knowledge about the treatment options and outcomes |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Thomas Pilgrim, Prof. | Contact | +41 31 632 50 00 | thomas.pilgrim@insel.ch | |
| Christoph Ryffel, Dr. med. | Contact | +41 31 632 50 00 | christoph.ryffel@insel.ch |
| Name | Affiliation | Role |
|---|---|---|
| Thomas Pilgrim, Prof. | Department of Cardiology, University Hospital Bern, Inselspital, Bern | Principal Investigator |
| Christoph Ryffel, Dr. med. | Department of Cardiology, University Hospital Bern, Inselspital, Bern |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bern University Hospital, Dep. of Cardiology | Recruiting | Bern | 3010 | Switzerland |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D001024 | Aortic Valve Stenosis |
| ID | Term |
|---|---|
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Usual Care | Other | Usual care will include baseline visits without a structured SDM approach. Usual care includes at least one decision making talk with a heart team member discussing information about the disease, treatment options as well as benefits and risks of each procedure. |
|
Assessed by 6 multiple-choice items (ranges from 0 to 6, with higher scores indicating a better outcome)
| 3 days post baseline visit |
| Patient procedural satisfaction | Assessed by Likert Scale (ranges from 1 to 5, with higher scores indicating a better outcome) | 3 days post baseline visit |
| Patient decisional satisfaction | Assessed by Likert Scale (ranges from 1 to 5, with higher scores indicating a better outcome) | 3 days post baseline visit; 30 days and 1 year post TAVR/SAVR |
| Incorporation of patient values | Assessed by values clarity subscore of the decisional conflict scale (ranges from 0 to 100, with higher scores indicating a worse outcome) | 3 days post baseline visit |
| Patient feeling of not being informed | Assessed by informed subscore of the decisional conflict scale (ranges from 0 to 100, with higher scores indicating a worse outcome) | 3 days post baseline visit |
| Quality of choice | Assessed by effective decision subscore of the decisional conflict scale (ranges from 0 to 100, with higher scores indicating a worse outcome) | 3 days post baseline visit |
| Patient decisional regret | Assessed by the decision regret scale (ranges from 0 to 100, with higher scores indicating a worse outcome) | 1 year post TAVR/SAVR |
| Patient health-related quality of life | Assessed by KCCQ 12 (Kansas City Cardiomyopathy Questionnaire) (ranges from 0 to 100, with higher scores indicating a better outcome) | 30 days post TAVR/SAVR |
| The proportion of patients choosing TAVR/SAVR | Number of participants choosing valve replacement by TAVR or SAVR | Baseline |
| The incidences of major clinical adverse events | All-cause mortality, stroke, transient ischemic attack, bleeding event, kidney injury, systemic embolism, myocardial infarction, new onset atrial fibrillation, permanent pacemaker implantation and intervention related to the device | 30 days and 1 year post TAVR/SAVR |
| D014694 |
| Ventricular Outflow Obstruction |